Danaher's Senior Notes Offerings To Fund BioPharma Buyout
Zacks Investment Research | Sep 04, 2019 08:54AM ET
Danaher Corporation (NYSE:DHR) yesterday announced about the pricing of €6.25 billion worth of senior notes, which will be guaranteed (fully and unconditionally) by it. It is worth noting here that DH Europe Finance II S.à r.l. — a wholly-owned subsidiary of Danaher — is the issuer of these senior notes. The offering will close on Sep 18, 2019.
The net proceeds of the offerings will be used to fund the acquisition of the BioPharma business — part of General Electric Company’s (NYSE:GE) GE Life Sciences business.
Inside the Headlines
As noted, the offerings will comprise €1.25 billion of 0.200% senior notes due to expire in 2026, €1.25 billion of 0.450% senior notes due to expire in 2028, €1.75 billion of 0.750% senior notes due to expire in 2031, €1.25 billion of 1.350% senior notes due to expire in 2039 and €0.75 billion of 1.800% senior notes due to expire in 2049.
About the pricing, notes due to expire in 2026 have been priced at 99.833% of principal amount, whereas, 2028 notes are priced at 99.751%, 2031 notes at 99.920%, 2039 notes at 99.461% and 2049 notes at 99.564%.
Interest on the senior notes will be paid annually. Payment will start from Mar 18, 2020, for 2026 notes and 2028 notes while will begin on Sep 18, 2020, for 2031 notes, 2039 notes and 2049 notes.
Ratings of the issuance are expected to be ‘Baa1’ by Moody's Investors Service and ‘BBB+’ by Standard & Poor’s Ratings Services.
Danaher anticipates securing net proceeds of roughly €6.197 billion from these notes offerings. These proceeds are net of underwriting discounts and issuance-related costs.
We believe that offerings of senior notes will increase Danaher’s debts and in turn, might inflate its financial obligations and hurt profitability. It is worth mentioning here that the company's long-term debt at the end of the second quarter stood at $10.1 billion.
Snapshot of BioPharma Buyout
It is worth noting here that Danaher agreed to acquire the BioPharma business for $21.4 billion on Feb 25. The buyout is anticipated to be completed in the fourth quarter of 2019. The acquired assets will be integrated with Danaher’s Life Sciences segment, complementing the company’s biologics workflow solutions.
The buyout is anticipated to boost its non-GAAP adjusted earnings by 45-50 cents per share in the first year of the completion of the deal.
In March 2019, Danaher raised funds from the issuance of common shares and preferred stocks to fund the BioPharma buyout. It raised net proceeds of $1.44 billion from 12.1 million of common share offerings and $1.60 billion from the issuance of 1.65 million of 4.75% Series A mandatory convertible preferred stocks. We believe that expanded share base caused by these offerings will likely dilute the company’s earnings in the year.
Get The News You Want
Zacks Rank and Stocks to Consider
With a market capitalization of approximately $102 billion, Danaher currently carries a Zacks Rank #3 (Hold). In the past 60 days, the Zacks Consensus Estimate for earnings has risen 0.4% to $4.79 for 2019 and 0.7% to $5.49 for 2020.
Danaher Corporation Price and Consensus
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.